IBSA
4.8.2022 13:02:07 CEST | Business Wire | Press release
Latest-generation Class40, “scow” bow, five months of production: the IBSA craft with which Alberto Bona will participate in the Route du Rhum in November was launched yesterday in La Trinité-Sur-Mer (Brittany, France). It’s the first project of the three-year program Sailing into the Future. Together that the ocean sailor started in early 2022, together with the Swiss pharmaceutical company.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220802005581/en/
Designed by Sam Manuard , one of the great French naval architects when it comes to ocean classes, the IBSA Class40 was built by the JPS Production shipyard. It’s a Mach 5 model, the latest evolution of Manuard’s Class40, and will be present at the start of the Route du Rhum as one of the most innovative and modern boats. Much attention will surely be drawn to the rounded bow, created with the aim of increasing performance when sailing downwind, but also the hull promises high performance, thanks to the shape of the water lines and appendages, designed to make it a fast all-rounder when reaching too. Distinctive is also the design of the cockpit, large and well protected: a choice that will allow the sailor to face navigation in the most comfortable and safe positions possible. “This boat perfectly reflects our approach to the program ”, summarised Alberto Bona . “It’s the result of the search for detail, of the improvement in every single aspect: we were looking for a fast hull, clearly at the limits of the box rule, reliable in all weather conditions and sufficiently innovative to make a difference ”.
The project Sailing into the Future. Together started from scratch last January with a partnership – that between IBSA and Alberto Bona – born on common grounds and values, with the aim of using sailing as a corporate communication vehicle towards the market and the nautical world. “Ingenuity, courage, innovation, responsibility are elements which unite us - explained Bona - for this reason we are facing together this challenge, which is clearly sporting but which also metaphorically represents the Company's history, philosophy and vision always turned towards the future, and is part of a path bringing IBSA ever closer to environmental and social sustainability, inclusion and integration. In this type of challenge, the solitary navigator stands out but, as in the industry, the commander exists as a function of his team. With IBSA, we first of all built a team ”.
As for the team , we start with Sidney Gavignet as a coach: the very experienced French navigator laid the foundations and objectives, with a strict rule: always be prepared, to foresee all aspects of the challenge, on land and at sea. “Sidney put us in a position to divide this great challenge into many small steps. A long roadmap of stages to be reached, training and testing in preparation for the start, since building a challenge like the Route du Rhum from scratch in seven months is extremely demanding ”. For the physical preparation part, Bona relied on Andrea Madaffari : he has been working with him for months on endurance and strength, as well as on the management of the energy peaks necessary during a regatta. “When sailing, one needs stamina and does a lot of pulling and hauling: you pull sheets and halyards, you need endurance and peak strength ”, explained Bona . “We are working on this, as well as on the aerobic part ”.
“The choice of Sam Manuard as a designer was virtually natural ,” recalled Bona , and is based on a solid relationship dating back to the time of the Mini class, on the sharing of a design vision and on the innovations that Bona was looking for his IBSA Class40. On the sails front, Bona chose Remi Aubrum , whom he entrusted with the choice of innovative materials, compatible with the rigorous box rule of the Class40. The last operational entry is that of the Boat Captain, the Breton expert Pierre-Edouard Regaud .
“In recent months we have all been working with the same philosophy, that of the goals to be achieved day by day. We are working on fatigue management, on finding the best solutions in all aspects of the project. It was a huge team effort, between us and IBSA , that led us to yesterday’s technical launch ”, said Bona .
In the afternoon, at 5 pm, the IBSA Class40 made on board a truck the short journey between the shipyard and the marina that will host it, which is located in front of “Casa IBSA”, the operational headquarters . Alberto Bona now has one month to set up the boat and to qualify, by sailing a thousand miles by the end of August. On September 9, the actual launch – the ceremony that will officially make the Class40 enter the IBSA world – will take place in La Trinité-sur-Mer . In mid-September, Bona will participate in the Malouine Lamotte regatta; then, he will transfer his operational base to Saint-Malo, from where the first regatta of the three-year program will start.
“We will talk to sailing enthusiasts and to the entire IBSA world, ” explained Bona , who also underlines the existence of a comprehensive sustainability project, in common with IBSA : “Navigators are experts in circular economy; they live for long periods on the ocean, they replace fossil fuels with solar and wind energy, they recycle everything they can, they live in true harmony with the sea, that they help protect: this is a very important message that, together with IBSA, we wish to promote and share, using the solo oceanic challenge as a great metaphor of what can and must be done for the environment ”.
In its program associated with sailing, IBSA is also committed to inclusiveness: in fact, the inclusive sailing project involving the Associazione Velabili based at the Circolo Velico Lago di Lugano (Switzerland), the Société des Régates d’Antibes (France) and the Yacht Club Punta Ala (Italy) has also been activated. The project aims to support inclusive sailing by promoting initiatives involving people with disabilities in experiences in contact with the sea and the sailing world, and consists in supporting a team of disabled sailors in participating in the Special Olympics World Games of 2023 and in the purchase of Hansa 303 boats for the Clubs of Punta Ala and Antibes.
IBSA
IBSA (Institut Biochimique SA ) is a Swiss multinational pharmaceutical Company, founded in 1945 in Lugano. Today, its products are present in over 90 Countries on 5 continents, through the Company’s 17 subsidiaries located in Europe, China, and the United States. The company has a consolidated turnover of 800 million CHF, and employs over 2,000 people between headquarters, subsidiaries and production sites. IBSA holds 90 families of approved patents, plus others under development, as well as a vast portfolio of products, covering 10 therapeutic areas: reproductive medicine, endocrinology, pain and inflammation, osteoarticular, aesthetic medicine, dermatology, uro-gynaecology, cardiometabolic, respiratory, consumer health. It is also one of the largest operators worldwide in the area of reproductive medicine, and one of the world’s leaders in hyaluronic acid-based products. IBSA has based its philosophy on four pillars: Person, Innovation, Quality and Responsibility.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220802005581/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
